Salbutamol in the Management of Asthma: A Review

• Type: Another Publication in an International Scientific Journal
• Date: 2022

Authors

Marques, L (Author) Other; Nuno Vale (Author) FMUP

Journal

Title: International Journal Of Molecular Sciences

Vol. 23

ISSN: 1661-6596

Publisher: MDPI

Indexing

ISI Web of Knowledge - 0 Citations

Scopus

Other information

Authenticus ID: P-00X-FTM

DOI: 10.3390/ijms232214207

Abstract (EN): Asthma is a common inflammatory disease of the lungs. The prevalence of asthma is increasing worldwide, and the tendency indicates that the number of asthma sufferers will soar in the coming years for several reasons, in particular, the lifestyles we have adopted that expose us to risk factors. Salbutamol is the first selective short-acting beta(2)-agonist (SABA) used as an alternative reliever in the treatment of asthma. Its therapeutic effect is based on its potent smooth muscle relaxant properties, which allow the inhibition of bronchial smooth muscle contraction and subsequent bronchodilation. Salbutamol can be administered orally, intravenously (IV), intramuscularly (IM), subcutaneously, or by inhalation. For this reason, the pharmacokinetic (PK) parameters-absorption, distribution, metabolism, and elimination-are highly diverse and, consequently, the efficacy and adverse effects also differ between each formulation. Here, we review the pharmacological profile of different salbutamol formulations, focusing on their efficacy and adverse effects for its original application, asthma.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 19